Date of Preparation: 8/1997



Yüklə 231,71 Kb.
səhifə2/4
tarix04.11.2017
ölçüsü231,71 Kb.
#30662
1   2   3   4

Review Articles:

1. Martino, S. Interferon. Osteopathic Medicine, 1980;5(11):55 80.




  1. Singhakowinta, A., Samal, B.A., Martino, S., Vaitkevicius, V.K. Is Hormone Sensitivity in Breast Cancer Related to Responsiveness to Cytotoxic Therapy? Reviews on Endocrine Related Cancer, 1982;11:15 19.




  1. Olevsky O, Martino S. Randomized clinical trials of raloxifene: Reducing the risk  of osteoporosis and breast cancer in postmenopausal women. Menopause. 2008;15(4 Suppl):790-796.




  1. Chung C, Martino S. Inflammatory Breast Cancer: the Road to Progress. Oncology. 2011;25(3):280-282

Books and Chapters:
1. Martino S, Baker LH, Pollard RJ, Correa JJ, DeMattia MD. Pulmonary Toxicity of Mitomycin. In: Mitomycin C Current Status and New Developments. Carter and Crooke, editors. Academic Press; 1979.p. 231 42.
2. Djuric Z, Martino S, Heibrun LK, Hart RW. Dietary modulation of oxidation DNA damage. In: Diet & Cancer: Markers, Prevention and Treatment. Marge B. Jacobs, editor. Plenum Press, New York, NY, 1994. p 71-73.


  1. Martino, S., The Role of Medical Oncology in an Interdisciplinary Comprehensive Breast Center. Surgical Oncology Clinics of North America, Volume 9, Number 2, April 2000.



Case Reports:
1. Martino S. Danazol induced hypercalcemia in breast cancer. Breast Cancer Research and Treatment, 1984;4(1):53.
2. Martino S, Singhakowinta A. Serial interferon alpha2 levels in serum and cerebrospinal fluid. Cancer Treatment Reports 1984;68:1057 58.


  1. Martino S, Samal, BA, Sohn YH. Reversible cardiac arrhythmia in a breast cancer patient treated with recombinant alpha interferon. Breast Cancer Research and Treatment 1985; 5:327 29.

4. Martino S, Young JD, Schilcher, RB. Treatment of a hyperbilirubinemic patient with doxorubicin: clinical and pharmacokinetic results. Hellan and S.A. Eccles, editors. In: Treatment of Metastases: Problems and Prospects Proceedings, 1985. p. 61 64, K.



PUBLISHED ABSTRACTS:
1. Martino S, Ownby H, Russo J, Roi L, Brennan MJ. Interrupted Pregnancy as an Indicator of Prognosis in Primary Breast Bancer. 5th Annual San Antonio Breast Cancer Symposium, Breast Cancer Research and Treatment. 2;15 19:#20, 1982 Nov 5 6.
2. Martino S, Samal BA, Singhakowinta A, Decker DA, Haas CD. In Vivo and In Vitro Study of AZQ in Advanced Breast Cancer. Proceedings of the American Society of Clinical Oncology, C 496:127, March 1984
3. Decker DA, Martino S, Subramanian MG. Inhibition of Androgen Steroidogenesis by Ketoconazole and Dexamethasone in Patients with Metastatic Prostate Cancer. Proceedings of the American Society of Clinical Oncology, C 633:162, March 1984.
4. Martino S, Schilcher RB, Ownby H, Russo J, Roi J, Brennan MJ. Interrupted Pregnancies (IP) as a Risk Factor in Primary Breast Cancer. J. Cancer Res Clin Oncol 1984;107(Suppl S 21).
5. Rooney,M, Singhakowinta A, Samal,BA, Martino S, Powers W. Multifocal Spinal Metastases from Breast Cancer: A Role for Whole Spine Irradiation? Proceedings of the American Society of Clinical Oncology, C 500:128, March 1984.
6. Schilcher RB, Decker DA, Evans L, Martino S, Kresge C, Young JD, Samal BA, Singhakowinta A. Influence of Age on Pharmacokinetics of 5 Fluorouracil (5FU). Breast Cancer Research and Treatment, 4(4)347,#52, 1984.


  1. Martino S, Ratanatharathorn V, Karanes C, Samal BA, Sohn YS, Rudnick SE. Reversible Arrhythmias Observed in Patients Treated with Recombinant DNA Alpha2 Interferon. Breast Cancer Research and Treatment, 4(4):338,#15, 1984.



  1. Martino S, Schilcher RB, Marier SJ, Evans LJ, Allen BJ, Young JD. Clinical and Pharmacokinetic Results in a Breast Cancer Patient with Hyperbilirubinemia Treated with Doxorubicin (DOX). Breast Cancer Research and Treatment, 4(4):347, #50, 1984.




  1. Martino S, Schilcher RB, Baker LH. Abgebrochene Schwangershaft (IP) Ein prognostisches Zeichen bei Patientinnen mit Primaerem Mammakarzinom, (17). Deutscher Krebskongress, Muenchen, FRG, March 7 10, Verh. Dtsch. Krebsgesellshaft 5, 1984.




  1. Martino S, Samal BA, Vaitkevicius VK. Phase II Study of Deoxydoxo­rubicin as First Line Therapy in Advanced Breast Cancer. Proceeding of the American Society of Clinical Oncology, C 259,4(4):67, March 1985.

11. Ratanatharathorn V, Karanes C, Al Sarraf M, Kish J, Ensley J, Pazdur R, Martino S, Young J, Rish P, Konrad M, Galicky P. Phase I trial of serine substituted recombinant DNA Beta Interferon (b IFN). Proceedings of AACR, 26:274,#1079, March 1985.


12. Martino S, Samal B, Vaitkevicius VK, Brennan MJ, Kresge C. 4`Deoxydoxorubicin (DxDx) as First Line Therapy for Metastatic Breast Cancer. Breast Cancer Research and Treatment, 6(2):171,#30, 1985.
13. Appel J, Singhakowinta A, Martino S, Bergsman KL, Samal BA. Repeat Combination Chemotherapy Following Adjuvant Use in Advanced Breast Cancer. Proceedings of the American Society of Clinical Oncology, 5:60,#234, May, 1986.
14. Fabian C, Park C, Jewell W, Kimler B, Lin F, Martino S, Osborne CK. Increase in proliferation fraction in breast cancer in vivo following estradiol vaginal suppositories as demonstrated by serial biopsies and flow cytometry. Proceedings of AACR, #29, March 1988.
15. Valdivieso M, Pazdur R, Flaherty L, Martino S, Redman B, Wozniak A, Herskovic A, Baker L. Intensive chemotherapy (INT RX) of small cell lung cancer (SCLC) with weekly etoposide (E), cyclophosphamide (C), hydroxydauno­rubicin (H) and oncovin (O) echo. Proceedings of the American Society of Clinical Oncology, Vol. 7, March 1988.
16. Flaherty L, Redman B, Chabot G, Martino S, Valdivieso M. Combination of dacarbazine (DTIC) and interleukin 2 (IL 2) in metastatic malignant melanoma (MMM). Proceedings of the American Society of Clinical Oncology, Vol. 7, March 1988
17. Ensley J, An ., Martino S, Weaver D, Benitez P, Valeriote F, Heilbrun L. Flow cytometry and cytology from fine needle aspirates of breasts from women at high risk for breast cancer. Breast Cancer Research and Treatment 12:87 105, 1988.
18. Martino S, Gala R, Valeriote F, Kim P, Heilbrun L, Kresge C, Boomer A. Prolactin as a predictor of breast cancer risk. Breast Cancer Research and Treatment, 12:87 105, 1988.


  1. Flaherty L, Redman B, Martino S, Valdivieso M, Rudolph A. Sequential recombinant interleukin 2 (rIL 2) and dacarbazine (DTIC) (RID 1) in metastatic malignant melanoma (MMM) clinical and immunologic results. Society for Biological Therapy, November 6-10, 1988.

20. Redman, B., Flaherty, L., Chou, T.H., Martino, S., Al Katib, A., Kaplan, J., Valdivieso, M. Phase I trial of combination therapy with recombinant interleukin 2 (IL 2) and recombinant interferon gamma (IFN g) in patients with cancer. Proceedings of the American Society of Clinical Oncology, 8:189, 1989.




  1. Martino S, Ensley JF, Weaver D, Benitez P, An T, Maciorowski Z, deBraud F, Hassan M, Kukuruga M, Singhakowinta A, Valeriote F. Cellular DNA content characteristics of needle aspirates from patients at high risk for developing breast cancer. Proceedings AACR, 30:#1018, 1989.




  1. Boomer A, Martino S, Krag G, Liang D, Bacus J, Reading B, Heilbrun L. Compliance to a 15% fat diet in women at risk for breast cancer. Breast Cancer Research and Treatment, 14:1, 1989.

23. Flaherty L, Wozniak A, Redman B, Martino S, Valdivieso M. Phase II-5FU, VP-16, Cisplatin (FED) in Metastatic Non-Small Cell Lung Cancer (NSCLC). Proceedings of the American Society of Clinical Oncology, 30:614, 1989.


24. Gordon CJ, Valdivieso M, Martino S, Redman BG, Flaherty L, Baker LH. Continuous intravenous 5 flourouracil (5 FU) infusion, weekly adriamycin (ADR) and oral cyclophosphamide (CTX) [FAC CI] in the treatment of metastatic carcinoma (MCB). Proceedings of the American Society of Clinical Oncology, 1(9):52, #200, 1990.
25. Valdivieso M, Wozniak A, Flaherty L, Pazdur R, Herskovic A, Heilbrun L, Redman B, Martino S, Baker L. Efficacy of weekly chemotherapy for small cell lung cancer (SCLC). Proceedings of the American Society of Clinical Oncology, 1(9):238, #920, 1990.
26. Martino S, Piccart MJ, Dodion PF, Chuang Stein C, Flaherty L, Redman B, Valdivieso M, English PA, Earhart RH. Phase II study of daily x 3 oral menogaril in advanced breast cancer. Proceedings of the American Society of Clinical Oncology, 1(9):52, #198, 1990.
27. Flaherty L, Robinson W, Redman B, Gonzales R, Martino S, Kraut M, Valdivieso M, Rudolph A. A phase II study of dacarbazine (DTIC), cisplatin (DDP), and outpatient interleukin 2 (IL 2) (RIDD 2) in metastatic malignant melanoma (M.M.M.). Proceedings of the American Society of Clinical Oncology, 1(9):187, #723, 1990.
28. Redman. B.G., Flaherty, L., Chou, T.H., Al Katib, A., Kraut, M., Martino, S., Chen, B., Kaplan, J. and Valdivieso, M. A phase I trial of recombinant Interleukin 2 combined with recombinant Interferon Gamma in patients with cancer. J. Clin. Oncol. 8:1269 1276, 1990.
29. Negendank W, Crowley MG, Al Katib A, Al Sarraf M, Martino S, Samal B, Zalupski MM, Baker LH. Assessment of 31P MRS chemotherapy response predictor in man using quantative spectral reproducibility criteria. Society of Magnetic Resonance in Medicine. New York, August, 1990.
30. Flaherty L, Redman B, Martino S, Kraut M, Simon M, Valdivieso M, Louie A. High-dose Decarbazine (DTIC) and CIsplatin (DDP) Alone and Combined With Outpatient Interleukin-2 (IL-2) in Metastatic Malignant Melanoma (MMM). Proceedings of the American Society of Clinical Oncology, 9:187, 1990.
31. Djuric Z, Heilbrun LK, Valeriote FA, Martino S. Effects of a low-fat diet on oxidative DNA damage in white blood cells of women at high risk for breast cancer. Oxidative Damage and Repair - Fifth Bi-Annual Meeting of the International Society for Free Radical Research. Free Radical Biol. Med., 9 (Suppl. 1):55, 1990.


  1. Chlebowski RT, Rose D, Blackburn G, Buzzard M, Khandekar J, York R, Insull W, Martino S, Elashoff R, Wynder E. Feasibility of using dietary fat intake reduction in adjuvant breast cancer management. Proceedings of the American Society of Clinical Oncology, 10:86, #217: 1991.

33. Lemanne D, Simon M, Martino S, Swanson M. Breast carcinoma in situ (CIS): Greater rise in ductal carcinoma in situ (DCIS) vs. lobular carcinoma in situ (LCIS). Proceedings of the American Society of Clinical Oncology, 10,(55):45, 1991.


34. Redman B, Flaherty L, Chou TH, Kraut M, Martino S., Simon ML, Groves E. Phase I trial of recombinant macrophage colony stimulating factor (M CSF) by rapid intravenous (IV) infusion in patients with cancer. Proceedings of the American Society of Clinical Oncology, 10:98,262 1991.
35. Simon, M., Schwartz, A., Martino, S., Swanson, M. Trends in the diagnosis of in situ breast cancer in the Detroit Metropolitan Area. Proceedings of the American Society of Clinical Oncology 10:132, #395, 1991.
36. Kraut M, Wozniak A, Flaherty L, Redman B, Samal B, Martino S, Simon M, Valdivieso M. Treatment of metastatic non small cell lung cancer (NSCLC) with mitomycin, etoposide, and cisplatin (MEP). Proceedings of the American Society of Clinical Oncology 10:262, #907, 1991.

7. Simon M, Lemanne D, Martino S, Schwartz A, Swanson GM. Trends in the Incidence of In Situ and Invasive Breast Cancer in the Detroit Metropolitan Area. Breast Cancer Research and Treatment, 19(2):165, 1991.


38. Simon MS, Martino S, Hussein M, Hoff M, Walt A, Meyer L. A survey of medical follow-up practice in women with early stage invasive breast cancer. Proceedings of the American Society of Clinical Oncology, 11:87,#175, 1992.
39. Flaherty L, Redman B, Martino S, Kraut M, Simon M, Samal B, Valdivieso M, Louie, A. High-dose decarbazine (DTIC) and cisplatin (DDP) alone and combined with outpatient interleukin (IL-2) in metastatic malignant melanoma (MMM). Proceedings of the American Society of Clinical Oncology, 11:350,#1206 1992.
40. Ensley JF, Weaver D, Benitez P, An T, Maciorowski Z, del Alonso M, Kukuruga M, Martino S. Dietary modulation of abnormal DNA histograms from breast aspirates of patients at high risk for developing breast cancer. Proceedings AACR, 33:133, 1992.
41. Simon M, Hoff M, Hussein M, Martino S. A study of clinical follow-up in women with early stage breast cancer. 15th Annual San Antonio Breast Cancer Symposium, 1992.
42. Chlebowski RT, Blackburn GL, Buzzard IM, Rose DP, Martino S, Khandekar JD, York MR, Jeffery RW, Elashoff RM, Wynder EL. Adherence to Dietary Fat Intake Reduction in Postmenopausal Women with Resected Breast Cancer. Proceedings of the American Society of Clinical Oncology, 12:269, #473, 1993.

43. Lichter A, Green S, Albain K, Hutchins L, Martino S. The Influence of Patient Characteristics, Socioeconomic (SES) Factors, Geography, and Systemic Risk on the Use of Breast Sparing Treatment in the Adjuvant Breast Cancer Studies. Proceedings of the American Society of Clinical Oncology, 13:62, #51, 1994.


44. Djuric Z, Simon MS, Luongo DA, LoRusso PM, Martino S. Oxidative DNA Damage in Blood DNA as a Marker of Breast Cancer Risk. Proceedings AACR 35:286. 1994.


  1. Djuric Z, Simon MS, Luongo DA, LoRossu PM, Martino S. Oxidative DNA damage in blood DNA as a marker of breast cancer risk. American Cancer Society, Michigan Division Meeting; Detroit, MI,

Nov. 18, 1994.


  1. Appelbaum FR, Armitage JO, Bierman PJ, Bitran JD, Buzdar A, Dubois R, Fisher RI, Gale RP, Hortobagyi GN, Jones SE, Lazar GS, Loh KK, Martino S, Peterson BA, Phillips GL, Portlock CS, Rosenblum D, Shipp MA, Shpall EJ, Spitzer G, Swain SM, Vaughn CB, Vogel C. Comparison of Rand-Delphi Analysis of Appropriateness of Bone Marrow and Blood Cell Autotransplants in Breast Cancer and Non-Hodgkin Lymphomas. Proceedings of the American Society of Clinical Oncology, 14:314, #922, 1995.




  1. Katato K,.Simon M, Martino S, Flaherty L, Redman B,. Lorusso P, Kellogg C, Hughes R. A Phase II Trial of Oral Altretamine (Hexalen) for the Treatment of Metastatic Breast Cancer. Proceedings of the American Society of Clinical Oncology, 14:119, #174, 1995

48. Taylor CW, Green S, Dalton WS, Martino S, Ingle JN, Robert NJ, Rector DJ, Osborne CK. A Multi-Center Randomized Trial of Zoladex Versus Surgical Ovariectomy in Pre-Menopausal Patients with Receptor Positive Metastatic Breast Cancer. Breast Cancer Research and Treatment 37:37, 1995.


49. CE Geyer Jr, SJ Green, C Moinpour, J O'Sullivan, D Goodwin, V Canfield, V Hamaski, S Martino. A Phase II Trial of Paclitaxel in Patients with Metastatic Refractory Carcinoma of the Breast: A Southwest Oncology Group (SWOG) Study. Proceedings of the American Society of Clinical Oncology 15:107, #92, 1996.
50. Rivkin SE, Green S, O'Sullivan J, Glucksberg H, Gadel-Mawla N, Constanzi JJ, Hoogstraten B, Athens J, Maloney T, Osborne CK, Vaughn CB, and Martino S. Adjuvant CMFVP Versus Melphalan for Operable Breast Cancer with Positive Axillary Nodes: 20-Year Results of a Southwest Oncology Group Study. Breast Cancer Research and Treatment, 41(3):219, #2, 1996.


  1. Albain K, Green S, Osborne K, Cobau C, Levine E, Ingle J, Pritchard K, Schneider D, O'Sullivan J, Hess E, Martino S. Tamoxifen (T) vs. Cyclophosphamide, Adriamycin, and 5-FU (CAF) plus Either Concurrent or Sequential T in Postmenopausal, Receptor (+), Node (+) Breast Cancer: A Southwest Oncology Group Phase III Intergroup Trial. Proceedings of the American Society of Clinical Oncology, 16:128a,#450, 1997.




  1. Sledge Jr GW, Neuberg D, Ingle J, Martino S, Wood W. Phase III Trial of Doxorubicin(A) vs. Paclitaxel(T) vs. Doxorubicin+Paclitaxel(A+T) as First-Line Therapy for Metastatic Breast Cancer(MBC): An Intergroup Trial. Proceedings of American Society of Clinical Oncology,16:1a, #2, 1997.

53. Elledge R, Green S, Allred D, Clark G, Ravdin P, Martino S, Osborne CK. ER and PGR by Ligand Binding Assay Compared with ER, PGR and PS2 by IHC in Predicting Response to Tamoxifen in Metastatic Breast Cancer. Breast Cancer Research and Treatment, 46(1):65, #258, 1997.




  1. Hutchins L, Green S, Ravdin P, Lew D, Martino S, Abeloff M, Lyss A, Henderson IC, Allred C, Dakhil S, Pierce I, Goodwin W, Thompson I, Rivkin S, Chapman R, Osborne CK. CMF versus CAF with and without Tamoxifen in High-Risk Node-Negative Breast Cancer Patients and a Natural History follow-up Study in Low-Risk Node-Negative Patients: First Results of Intergroup Trial Int 0102: A Southwest Oncology Group Study. Proceedings of the American Society of Clinical Oncology, 17:1a, #2, 1998.




  1. P.M. Ravdin, S. Green, K.S. Albain, V. Boucher, J. Ingle, K. Pritchard, L. Shepard, N. Davidson, D.F. Hayes,G.M. Clark, S. Martino, C.K. Osborne, D.C. Allred. Initial Report of the SWOG Biological Correlative Study of C-ERBB-2 Expression as a Predictor of Outcome in a Trial Comparing Adjuvant CAF T with Tamoxifen (T) alone. Proceedings of the American Society of Clinical Oncology 17:97a,#374, 1998.




  1. Henderson IC, Berry D, Demetri G, Cirrincione C, Goldstein L, Martino S, Ingel JN, Cooper MR, Canellos G, Borden E, Fleming G, Holland JF, Graziano S, Carpenter J, Muss H, Norton L. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC). Proceedings of the American Society of Clinical Oncology, 17:101a, 390A, 1998.




  1. Silverstein MJ, Lagios MD, Waisman JR, Martino S, Baron P, Lewinsky BS, Colburn WJ,. Gamagami P. Margin Width: A Critical Determinant of Local Control in Patients with Ductal Carcinoma in Situ (DCIS) of the Breast. Proceedings of the American Society of Clinical Oncology, 17:120a, #460, 1998.




  1. Davidson N, O’Neil A, Habermann T, Osborne CK, Martino S, White D, Abeloff MD for ECOG. Effect of Chemohormonal Therapy in Premenopausal, Node (+), Receptor (+) Breast Cancer: An Eastern Cooperative Oncology Group Phase III Intergroup Trial (E5188, INT-0101). Proceedings of the American Society of Clinical Oncology 18:67a, #249, 1999.




  1. Rivkin SE, Green S, Lew D, Glucksberg H, Gad-el-Mawla N, Costanzi J J, Hoogstraten B, Athens J, Maloney T, Osborne CK, Vaughn CB, Martino S. Adjuvant CMFVP Versus Melphalan for Operable Breast Cancer with Positive Axillary Nodes: 23-Year Results of a Southwest Oncology Group Study. Proceedings of the American Society of Clinical Oncology 18:69a, #259, 1999.




  1. Hughes LL, Gray RJ, Solin LJ, Robert NJ, Martino S, Tripathy D, Ingle JN, Wood WC, for ECOG, SWOG, CALGB, and NCCTG. Efficacy of Irradiation for Ovarian Ablation: Results of a Breast Intergroup Study. Breast Cancer Research and Treatment, 57(1):107, #440, 1999.




  1. Hutchins L, Green S, Ravdin P, Lew D, Martino S. Abeloff M, Lyss A, Henderson C, Allred C, Dakhil S, Pierce I, Goodwin W, Caton J, Rivkin S, Chapman R, and Osborne K. Southwest Oncology Group Operations Office, San Antonio, TX. CMF Versus CAF + Tamoxifen in High-Risk Node-Negative Breast Cancer Patients and a Natural History Follow-up Study in Low-Risk Node-Negative Patients : Update of Tamoxifen Results. Breast Cancer Research and Treatment, 57(1):25, #1, 1999.




  1. Ellis GK, Green SJ, Livingston RB, Budd GT, Rivkin SE, Giguere JK, Gandara DR, Weiss GR, Martino S. Neoadjuvant Doxorubicin, Cyclophosphamide and G-CSF (AC+G) for Locally Advanced Breast Cancer (LABC), a Southwest Oncology Group Phase II Study. Proceedings of the American Society of Clinical Oncology, 19:85a, #326, 2000.




  1. Cobleigh A, Gray R, Graham M, Norton L, Martino S, Budd GT, Ingle JN, Davidson NE, Wood WC. Fenretinide (FEN) vs Placebo in Postmenopausal Breast Cancer Patients Receiving Adjuvant Tamoxifen (TAM), an Eastern Cooperative Oncology Group Phase III Intergroup Trial (EB193, INT-0151). Proceedings of the American Society of Clinical Oncology, 19:86a, #328, 2000.




  1. Taback B, Giuliano AE, Nguyen DT, Nakayama T, Hansen N, Martino S, Fournier PJ, Hoon D. Tumor Related Free DNA Microsatellites Detected in Breast Cancer Patients Serum Correlates with Disease Progression. Proceedings of the American Society of Clinical Oncology, 19:606a, #2385, 2000.




  1. Ellerbroek N, Martino S, Mautner B, Botnick L. Adjuvant Paclitaxel and Radiation Therapy for Patients with Intact Breast Feasibility of Concurrent Treatment. Proceedings of the American Society of Clinical Oncology, 20:11b, #1790, 2001.




  1. Albain K, Green S, Ravdin P, Osborne CK, Cobau C, Levine E, Ingle J, Pritchard K, Schneider D, Abeloff M, Norton L, Lew D, Martino S. Overall Survival After Cyclophosphamide, Adriamycin, 5-FU, and Tamoxifen (CAFT) is Superior to T Alone in Postmenopausal, Receptor (+), Node (+) Breast Cancer: New Findings From Phase III Southwest Oncology Group Intergroup Trial SS8814. Proceedings of the American Society of Clinical Oncology, 20:24a, #94, 2001.




  1. Goodwin JW, Green SJ, Giarritta S, Giguere JK, Hoelzer K, Bearden J, Livingston RN, Gralow J, Ganz PA, Martino S, Albain KS. Double Blind Phase III Trial of Placebo (P) vs. Megestrol Acetate (MA) 20 mg. Vs. MA 40 mg as Treatment for Symptoms of Ovarian Failure in Breast Cancer Survivors: Initial Results of Southwest Oncology Group S9626. Breast Cancer Research and Treatment, 24th Annual San Antonio Breast Cancer Symposium, 69(3): 292, #462, 2001.




  1. Martino S, Irwin D, Rowland K. The John Wayne Cancer Institute, Santa Monica, CA; Alta Bates Comprehensive Cancer Center, Berkeley, CA; Carle Clinic, Urbana, IL. A Phase III Trial of Taxol (T)/Doxorubicin/Cytoxan (D) (Two Dose Levels) Versus Doxorubicin/Cytoxan (C) Followed by a Comparison of Weekly Versus Q3 Weekly T in Patients (pts) with Metastatic Breast Cancer (MBC). Proceedings of the American Society of Clinical Oncology, 21(1):56a, #220, 2002.




  1. Haskell CM, Green SJ, Sledge Jr. GW, Shapiro CL, Ingle JN, Lew D, Martino S, Livingston RB, and Osborne, CK for SWOG, ECOG, CALGB and the NCCTG. Phase III Comparison of Adjuvant High-dose Doxorubicin plus Cyclophosphamide (AC) Versus Sequential Doxorubicin Followed by Cyclophosphamide (A>C) in Breast Cancer Patients with 0-3 Positive Nodes (Intergroup 0137). Proceedings of the American Society of Clinical Oncology, 21(1):36a, #142, 2002.



  2. Albain KS, Green SJ, Ravdin PM, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Schneider DJ, Abeloff MD, Norton L, Henderson IC, Lew D, Livingston RB, Martino S, and Osborne CK for SWOG, ECOG, CALGB, NCCTG, NCIC-CTG, Loyola University Medical Center, Maywood, IL. Adjuvant Chemohormonal Therapy for Primary Breast Cancer Should be Sequential Instead of Concurrent: Initial Results from Intergroup Trial 0100 (SWOG-8814). Proceedings of the American Society of Clinical Oncology, 21(l):37a, #143, 2002




  1. Stadtmauer EA, O’Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, Brodsky I, Martino S, Lazarus HM, Erban JK, Sickles C, Glick JH. Conventional-dose Chemotherapy Compared with High-dose Chemotherapy (HDC) Plus Autologous Stem-cell Transplantation (SCT) for Metastatic Breast Cancer: 5-year Update of the ‘Philadelphia Trial’ (PBT-1). Proceedings of the American Society of Clinical Oncology, 21(1):43a, #169, 2002.




  1. Ganz PA, Green SJ, Hutchins L, Martino S, Gralow J, Livingston R, Albain KS (from the Southwest Oncology Group). Late cardiac effects of adjuvant CMF vs CAF in women with node negative breast cancer treated on SWOG 8897: initial results from SWOG 9342. Breast Cancer Research and Treatment, 25th Annual San Antonio Breast Cancer Symposium, 76(1):S157, #639, 2002.



  1. Citron M, Berry D, Cirrincione C, Carpenter J, Hudis C, Gradishar W, Ingle J, Martino S, Winder E, Muss H, Norton L. Superiority of dose-dense (DD) over conventional scheduling (CS) and equivalence of sequential (SC) vs. combination adjuvant chemotherapy (CC) for node-positive breast cancer (CALGB 9741, INT C9741). Breast Cancer Research and Treatment, 25th Annual San Antonio Breast Cancer Symposium, 76(1):S32, #15, December 2002.




  1. Arpino G, Green S, Allred DC, Ravdin P, Lew D, Martino S, Osborne CK, Elledge R. ErbB-2 amplification, ErbB-1 expression and tamoxifen response in ER-positive metastatic breast cancer: a SWOG study. Breast Cancer Research and Treatment, 25th Annual San Antonio Breast Cancer Symposium, 76(1):S67, #232, December 2002.




  1. Davidson NE, O’Neill A, Vukov A, Osborne CK, Martino S, White D, Abeloff M. Chemohormonal therapy in premenopausal node-positive, receptor-positive breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101). Proceedings of the American Society of Clinical Oncology, 22:5, #15, 2003.




  1. Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Ingle JN, Rodeheffer RJ, Gersh BJ, Jaffe AS. Effect of doxorubicin plus cyclophosphamide (AC) on left ventricular ejection fraction (LVEF) in the NCCTG N9831 Intergroup Adjuvant Trial. Proceedings of the American Society of Clinical Oncology, 22:19, #75, 2003.




  1. Robert NJ, Wang M, Cella D, Martino S, Tripathy D, Ingle J, Solin LJ, Wood WC. Phase III comparison of tamoxifen versus tamoxifen with ovarian ablation in premenopausal women with axillary node-negative receptor-positive breast cancer  3 cm. Proceedings of the American Society of Clinical Oncology, 22:5, #16, 2003.




  1. Goldstein LJ, O’Neill A, Sparano JA, Perez EA, Shulman LN, Martino S, Wolff AC, Davidson NE. LVEF assessment of adjuvant doxorubicin/cyclophosphamide (AC) vs. doxorubicin/docetaxel (AT) in early stage breast cancer: Cardiac safety results of ECOG 2197. Proceedings of the American Society of Clinical Oncology, 22:19, #73, 2003.




  1. Budd G, Green S, Livingston R, O’Bryan R, Martino S, Abeloff M, Rinehart J, Harris J, Tormey D, Osbourne CK. Long-term follow up of SWOG 8313: CMFVP vs FAC-M as adjuvant therapy of node- positive, ER-negative breast cancer. Breast Cancer Research and Treatment. 26th Annual San Antonio Breast Cancer Symposium, 82(1):S28, #132, December 2003.




  1. Albain KS, Unger JM, Hutchins LF, Rivkin SE, Martino S, Livingston RB, Osborne CK. Outcome of African Americans on Southwest Oncology Group (SWOG) breast cancer adjuvant therapy trials. Breast Cancer Research and Treatment. 26th Annual San Antonio Breast Cancer Symposium, 82(1):S12, #21, December 2003.




  1. McNabb M, Martino S, Secrest RJ, Bryant K, Powles T, Mershon J. Baseline breast cancer risk demographics and methodology for the Raloxifene use for the heart (RUTH) and continuing outcomes relevant to Evista (CORE) Studies. Two breast cancer prevention trials. Int J Gynecol Cancer, 13(S1):2, 2003.




  1. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pater JL. Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. Proceedings of the American Society of Clinical Oncology, 4:87, #847, 2004.




  1. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon JL, Disch D, Secrest RJ, Cummings SR. Incidence of invasive breast cancer following 8 years of raloxifene therapy in postmenopausal women with osteoporosis: Results from the Continuing Outcomes Relevant to Evista (CORE) trial. Proceedings of the American Society of Clinical Oncology, 4:97, #1000, 2004.




  1. Perez E, Martino S. HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial. Proceedings of the American Society of Clinical Oncology, 4:18, #567, 2004.



  1. Unger JM, Crowley JJ, Coltman CA, Hutchins LF, Martino S, Macdonald JS, Gandara DS, Crawford ED, Livingston RB, Albain KS. Accrual patterns of the Southwest Oncology Group (SWOG) by sex, race/ethnicity, and age: updated and expanded analyses. Proceedings of the American Society of Clinical Oncology, 4:520, #6014, 2004.




  1. Cauley JA, Martino S, Barrett-Connor E, Powles TJ, Mershon JL, Disch D, Secrest RJ, Cummings SR. Effect of raloxifene on invasive breast cancer incidence in postmenopausal women stratified by Gail risk assessment: Results of the Continuing Outcomes of Relevant to Evista® (CORE) trial. Proceedings of the American Society of Clinical Oncology, 4:101, #1018, 2004.




  1. Whelan T, Goss P, Ingle J, Pater J, Shepherd L, Palmer M, Tu D, Robert N, Martino S, Muss H. Assessment of quality of life (QOL) in MA.17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen. Proceedings of the American Society of Clinical Oncology, 4:6, #517, 2004.




  1. Miller DV, Jenkins RB, Lingle WL, Davidson NE, Kaufman PA, Martino S, Dakhil SR, Perez EA. Focal HER2/neu amplified clones partially account for discordance between immunohistochemistry and fluorescence in-situ hybridization results: Data from NCCTG N9831 Intergroup Adjuvant Trial. Proceedings of the American Society of Clinical Oncology, 4:19, #568, 2004.




  1. Martino S, Powles T, Cauley J, Mershon J, Disch D, Secrest R, Cummings S. Effect of raloxifene on incidence of invasive breast cancer in postmenopausal women stratified by baseline serum estradiol: Results of the Continuing Outcomes Relevant to Evista® trial. Breast Cancer Research and Treatment (26th San Antonio Breast Cancer Symposium), 88(1):S14, #22, 2004.




  1. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez E, Muss HB, Norton L, Hudis C, Winer EP. Effects of improvements in chemotherapy on disease-free and overall survival of estrogen-receptor negative, node-positive, early stage breast cancer: 20-year Experience of the Cancer and Leukemia Group B (CALGB) and U.S. Breast Intergroup. Breast Cancer Research and Treatment (26th San Antonio Breast Cancer Symposium), 88(1):S17, #29, 2004.




  1. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tzer RG, Palmer MJ, Shepherd LE, Tu D, Goss PE. Effect of letrozole versus placebo on bone mineral density in women completing >5 years (yrs) of adjuvant tamoxifen: ncic ctg ma.17b. Breast Cancer Research and Treatment (26th San Antonio Breast Cancer Symposium), 88(1):S36, #404, 2004.




  1. Gotay CC, Moinpour CM, Jiang CS, Ankerst DP, Coleman D, Martino S, Taylor B, Bearden J, Dakhil S, Gross H, Albain KS. Enhancing well-being during breast cancer recurrence: preliminary finds from a phase III study. Breast Cancer Research and Treatment (26th San Antonio Breast Cancer Symposium), 88(1):S140, #3080, 2004.




  1. Albain K, Barlow W, O’Malley, F, Siziopikou K, Yeh I-T, Ravdin P, Lew D, Farrar W, Burton G, Ketchel S, Cobau C, Levine E, Ingle J, Pritchard K, Lichter A, Schneider D, Abeloff M, Henderson IC, Norton L, Hayes D, Green S, Livingston R, Martino S, Osborne CK, Allred DC. Concurrent (CAFT) versus sequential (CAF T) chemohormonal therapy (cyclophosphamide, dosorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, nod-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase II intergroup trial 0100 (SWOG-8814). Breast Cancer Research and Treatment (26th San Antonio Breast Cancer Symposium), 88(1); addendum sheet.




  1. Martino S, Disch D, Dowsett S, Mershon J. Raloxifene and breast cancer risk reduction based on breast cancer family history. Obstectrics & Gynecology, 105(4):p4S, 2005.




  1. Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Dakhil SR, Ingle JN, Hillman DW, Rodeheffer RJ, Gersh BJ, Jaffe AS. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant Trastuzumab trial. Proceedings of the American Society of Clinical Oncology, 23(16S, I of III):17s, #556, 2005.



  1. Goldstein LJ, O’Neill A, Sparano JA, Perez EA, Shulman LN, Martino S, Davidson NE. E2197: Phase III AT (doxorubucin / docetaxel) vs. AC (doxorubicin / cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. Proceedings of the American Society of Clinical Oncology, 23(16S, I of III):7s, #512, 2005.




  1. Bearman SI, Green S, Gralow J, Barlow W, Hudis C, Wolff A, Ingle J, Hortobagyi G, Livingston R, Martino S. SWOG/Intergroup 9623: A phase III comparison of intensive sequential chemotherapy to high dose chemotherapy and autologous hematopoietic progenitor cell support (AHPCS) for primary breast cancer in women with >4 involved axillary lymph nodes. Proceedings of the American Society of Clinical Oncology, 23(16S, I of III):21s, #572, 2005.




  1. Martino S, Disch D, Dowsett S, Mershon J. Effect of raloxifene on invasive breast cancer incidence in postmenopausal women stratified by age (<65 and >65 years). Proceedings of the American Society of Clinical Oncology, 23(16S, I of III):108s, #1009, 2005.




  1. Hudis C, Citron M, Berry D, Cirrincione C, Gradishar W, Davidson N, Martino S, Livingston R, Ingle J, Perez E, Abrams J, Schilsky R, Ellis M, Muss H, Norton L, Winer E. Five year follow-up of INT C9741: Dose-dense (DD) chemotherapy (CRx) is safe and effective. Breast Cancer Research and Treatment (28th San Antonio Breast Cancer Symposium), 94(1):S20, #41, 2005.



  1. Perez EA, Suman VJ, Davidson N, Martino S, Kaufman P. Concurrent trastuzumab and paclitaxel treatment improves disease-free survival in resected HER2-positive breast cancer: NCCTG interim analysis. (Abstract # 264). ECCO 2005;3(2):74.




  1. Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Dakhil SR, Ingle JN, Rodeheffer RJ, Gersh BJ, Jaffe AS. Exploratory analysis from NCCTG N9831: Do clinical and laboratory characteristics predict cardiac toxicity of trastuzumab when administered as a component of adjuvant therapy? Breast Cancer Research and Treatment (28th San Antonio Breast Cancer Symposium), 94(1):S96, #2038, 2005




  1. Mershon J, Disch D, Dowsett S, Martino S. Effect of Raloxifene on invasive breast cancer incidence in postmenopausal women from USA and Canada. Obstet Gynecol. ( American College of Gynecology 54th Annual Meeting) 107:81S-82S 2006.




  1. Hayes DF, Thor A, Dressler L, Weaver D, Broadwater G, Goldstein L, Martino S, Ingle J, Henderson IC, Berry D. HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344. Proceedings of the American Society of Clinical Oncology, 24(18S, I of II):5s, #510, 2006.

  2. Ambrosone CB, Barlow W, Yeh I-T, Hayes DF, Davis W, Rae JM, Hutchins LF, Livingston R, Ravdin P, Martino S, Osborne K, Abeloff M, Lyss AP, Albain K.. Pharmacogenetics and breast cancer treatment outcomes: results on oxidative stress-related genotypes (MPO, MnSOD) from a southwest oncology group intergroup trial (INT-0102). Breast Cancer Research and Treatment (29th Annual San Antonio Breast Cancer Symposium). 100(1):S18, #37, 2006

  3. Hershman D, Unger J, Barlow W, Hutchins L, Martino S, Abeloff M, Norton L, Livingston R, Osborne K, Albain K, Treatment quality and outcome of African American vs. European American Breast Cancer Patients: Retrospective Analysis of Southwest Oncology Group Studies S8814/S8897. Breast Cancer Research and Treatment (29th Annual San Antonio Breast Cancer Symposium) 100(1):,S140, #3049;2006.

  4. Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, Whelan T, Palmer MJ, Piccart MJ, Shapher LE, Prithcard KI, He Z, Goss PE. The benefits of letrozole in postmenopausal women with early stage breast cancer who have had five years of tamoxifen are independent of age. Breast Cancer Research and Treatment (29th Annual San Antonio Breast Cancer Symposium). 100(1):S23, #102, 2006.

  5. Perez EA, Romond EH, Suman VJ, Jeong J, Davidson NE, Geyer CE, Martino S, Mamounas EP, Kauffman PA, Wolmark N. Updated Results of the comnined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. Journal of Clinical Oncology 2007: 25(18S): 6S#512

  6. Sparano J.A., Wang M., Martino S., Jones V., Perez E., Saphner T., Wolff A,C., Sledge G.W. Jr, Wood W.C., Davidson N.E.. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: Results of Intergroup Trial E1199. Journal of Clinical Oncology 2007; 25(18S): 6S #516

  7. Kutteh LA, Hobday T, Jaffe A, LaPlant B, Hillman D, Kaufman P, Davidson N, Martino S, Moreno A, Perez E. A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER-2 positive breast cancer. Journal of Clinical Oncology 2007: 25(18S): 6S #579

  8. Slovak ML, Bedell V, Lew D, Albain KS, Ellis GK, Livingston R, Martino S, Perez E, Sher D, Stock W. Screening for clonal hematopoiesis as a predictive marker for development of t-AML following adjuvant therapy for breast cancer (S0012). Journal of Clinical Oncology 2007: 25(18S): 598s #11051

  9. Moreno-Aspitia, Dueck A, Lingle W, Kutteh K, Tenner N, Davidson S, Martino S, Kaufman WP, Carney E, Perez E. Serum HER2 (sHER2) levels in early stage HER@ neu (+) breast cancer (HER2+BC). Results from NCCTG adjuvant Intergrioup trial N9831. Journal of Clinical Oncology 2008; 26: # 529.

  10. Perez EA, Reinholz MM, Dueck AC, Wiktor AE, Wilma LL, Nancy ED, Martino S, Kaufman PA, Kutteh LA & Jenkins RB. c-MYC (MYC) amplification and correlation with patient outcome in early stage HER2+ breast cancer (BC) from the NCCTG adjvant Intergroup trial N9831. Cancer Res, 2008; 69(Suppl.): (2) Abstract #56.

  11. Sparano JA, Gray R, Goldstein LJ, Childs BH, Bugarini R, Rowley S, Baker J, Shak S, Badve S, Baehner FL, Perez E, Shulman LN, Martino S, Sledge GW, Davidson NE. Grb7-Dependent Pathways are Potential Therapeutic Targets in Triple Negative Breast Cancer. Cancer Res, 2008; 69(Suppl.): (2) Abstract #25.



  12. WR Sukov, DV Miller, AC Dueck, KS Tenner, RB Jenkins, NE Davidson, PA Kaufman, S Martino, SR Dakhil, V Roy, EA Perez. Breast Tumors with Focal HER2 Amplified Clones Show Similar Response to Trastuxzumab Therapy as Diffusely HER2 Amplified Breast Tumors; Data from NCCTG N9831 Intergroup Adjuvant Trial. J Clin Oncol 27:15s, 2009 (suppl; abstr 520)




  1. J.A. Sparano, R. Gray, L.J.Goldstein, B.H. Childs, D. Brassard, R. Bugarini, S. Rowley, J.Baker, S. Shak, S.Badve, F.L. Baehner, , P. Kenny, E. Perez, L.N. Shulman, S. Martino, G.W.Sledge, Jr., and N.E. Davidson. Gene Expression Profiling of Phenotypically-Defined Hormone-Receptor Positive Breast Cancer: Evidence for Increased Transcriptional Activity of the Insulin Growth Factor Receptor Pathway and Other Pathways (Submitted June 2009 to SABCS 2009)




  1. JA Sparano, M Wang, V Stearns, S Martino, V Jones, EA Perez, T Saphner, AC Wolff, GW. Sledge Jr., WC Wood, and NE. Davidson. Black race is associated with a worse outcome in patients with hormone receptor positive, HER2-normal breast cancer treated with adjuvant chemohormonal therapy. (Submitted June 2009 to SABCS 2009)




  1. Monica M Reinholz, Amylou C Dueck, Anne E Wiktor, Wilma L Lingle, Robert B Jenkins, Nancy E Davidson, Silvana Martino, Peter A Kaufman, Leila A Kutteh, George W Sledge, Lyndsay N Harris, Julie R Gralow, Xochiquetzal Geiger, Edith A Perez. c-MYC (MYC) protein expression and associations with trastuzumab benefit in early-stage, HER2+ breast cancer in context of the NCCTG adjuvant trial, N9831. (Submitted June 2010 to San Antonio Breast Cancer Symposium)




  1. Ravdin P, Martino S, Pegram M, Robert N, Swain S, Janssen D, Bowser A, Mortimer J, Carlson R. Utilization and clinical practice impact of an interactive tool for guiding choice of systemic adjuvant treatment for patients with early breast cancer. J Clin Oncol 29:15s, 2011 (abstr 6063)




  1. Perez E, DueckA, Reinholz M, Chen B, Geiger X, Jenkins R, Lingle W, Andorfer C, Davidson N, Martino S, Kaufman P, Kutteh L, Sledge G, Harris L, Gralow J, McCullough A. Effect of PTEN protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG adjuvant trial N9831. J Clin Oncol 29:15s, 2011 (abstr10504)




  1. Reinholtz M, Martino S, et al. Effect of IGF1R protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG N9831 trial. J Clin Oncol 29:15s, 2011 (abstr 10503)




  1. Schneider B, Wang M, Stearns V, Martino S, JonesV, Perez E, Saphner T, Wolff A, Sledge G, Wood W, Davdson N, Sparano J. Relationship between taxane induced neuropathy and clinical outcomes after adjuvant chemotherapy. Breast Cancer Symposium 2011 Proceedings,2011, (abstr 270)




  1. Romond E H, Suman V J, Jeong J-H, Sledge G, Geyer Jr CE, Rastogi P, Gralow J, Martino S, Swain S M, Winer E, Colon-Otero G, Zujewski J, Paik S, Mamounas E, Wolmark N, Perez E A. Trastuzumab Plus Adjuvant Chemotherapy for HER2-Positive Breast Cancer: Final Planned Joint Analysis of Overall Survival (OS) from NSABP B-31 and NCCTG N9831. (submitted to San Antonio Breast Symposium, 2012)



PRESENTATIONS:

Yüklə 231,71 Kb.

Dostları ilə paylaş:
1   2   3   4



Verilənlər bazası müəlliflik hüququ ilə müdafiə olunur ©muhaz.org 2024
rəhbərliyinə müraciət
gir | qeydiyyatdan keç
    Ana səhifə
Dərs
Dərslik
Guide
Kompozisiya
Mücərrəd
Mühazirə
Qaydalar
Referat
Report
Request
Review

yükləyin